CC
VRNA

Centiva Capital’s Verona Pharma VRNA Stock Holding History

Centiva Capital’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,017
Closed -$382K – 2071
2025
Q1 		$382K Buy
+6,017
New +$360K 0.01% 957
2024
Q4 		– Sell
-10,262
Closed -$295K – 2449
2024
Q3 		$295K Sell
10,262
-6,135
-37% -$151K 0.01% 1588
2024
Q2 		$237K Buy
16,397
+4,242
+35% +$61.9K ﹤0.01% 1595
2024
Q1 		$196K Buy
+12,155
New +$210K ﹤0.01% 1485

Other funds holding VRNA

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Centiva Capital's VRNA Position: Q2 2025 in Review

Centiva Capital sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 6,017 shares — an estimated $382K sold.

Centiva Capital first reported a position in VRNA in Q1 2024 and held it in 4 quarters. The position peaked at $382K in Q1 2025. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

  • Centiva Capital reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 6,017 Verona Pharma shares in Q2 2025, an estimated $382K.
  • Centiva Capital first reported a position in Verona Pharma in Q1 2024 and held it in 4 quarters.
  • Centiva Capital's Verona Pharma position peaked at $382K in Q1 2025.
  • 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.